Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2. The COViNEPH Project

Dębska‐Ślizień, Alicja; Muchlado, Marta; Ślizień, Zuzanna; Kubanek, Alicja; Piotrowska, Magdalena; Dąbrowska, Małgorzata; Bzoma, Beata; Konopa, Joanna; Renke, Marcin; Biedunkiewicz, Bogdan; Tylicki, Leszek

doi:10.20452/pamw.16142

Cited by 8 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with the previous observation in various populations, patients with a prior SARS-CoV-2 infection responded better to vaccination [18][19][20]. This applies not only to the development of antibody-mediated response but also to its magnitude.…”

Section: Discussionsupporting

confidence: 89%

Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: The immune response to the primary (two-dose) series of mRNA COVID-19 vaccines in kidney transplant recipients (KTRs) is very weak. We conducted a longitudinal observational study to compare the humoral response to a third, additional primary dose of mRNA vaccines between infection-naïve (IN-KTRs) and previously infected KTRs (PI-KTRs). Methods: We measured the levels of anti-spike (anti-s) IgG antibodies before and 14–21 days after the third dose and, in the secondary analysis, we compared the antibody response to BNT162b2 versus mRNA-1273. The reactogenicity assessment included solicited local and systemic reactions. Results: A total of 112 KTRs were enrolled, including 83 IN-KTR and 29 PI-KTR, among whom seroconversion in anti-s antibodies after the primary two-dose vaccination was achieved in 45.78% and 100% of cases, respectively. After three months, a waning antibodies titer by 67.4% (IN-KTR) and 7.5% (PI-KTR) was observed. After the third dose of the mRNA vaccine, 71.08% (59/83) of IN-KTR and 96.5% (28/29) of PI-KTR samples were seroconverted with a median anti-s titer of 468.0 (195.0–1620.0) BAU/mL and 1629.0 (1205–1815) BAU/mL, respectively. Of those IN-KTR in whom the primary vaccination failed, 46.67% (21/45) of patients achieved seroconversion after the third dose. No serious adverse events after the third dose were reported. In strata analyses, after the third dose, 66% (40/60) of patients vaccinated with BNT162b2 and 82.6% (19/23) of patients vaccinated with mRNA-1273 seroconverted with a median anti-s titer of 384.5 (144–837) BAU/mL and 1620 (671–2040) BAU/mL, respectively. Conclusions: The use of a third dose of mRNA vaccine may be of benefit for KTR, especially for those in whom the primary vaccination failed. Vaccines with a higher dose of mRNA and a longer interval between doses of the primary vaccination, such as mRNA-1273, seem to be the preparations of choice in immunocompromised individuals.

show abstract

Section: Discussionsupporting

confidence: 89%

Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of those, 877 patients received the mRNA-1273 vaccine. The anti-SARS-CoV-2 antibodies against receptor-binding domain (RBD) and/or spike protein were detected with the Elecsys (anti-RBD; Roche, Basel, Switzerland) or the Euroimmun (Lübeck, Germany) test (anti-S1) in three studies [ 15 , 17 , 19 ], with only the Euroimmun test in one study [ 20 ], with the Alimiti (anti-RBD; Abbott, Abbott Park, IL, USA) in one study [ 18 ], with the DiaSorin (Saluggia, Italy) anti-trimeric S-protein test [ 16 ] or Ortho Clinical Diagnostics (Raritan, NJ, USA) anti-SARS-CoV-2 Spike Ig assay [ 14 ] and with an in-house-designed Luminex bead assay (anti-RBD; Austin, TX, USA) [ 21 ]. The median time between the second vaccination and measuring the antibody response varied between 17 and 94 days after the second vaccine administration.…”

Section: Resultsmentioning

confidence: 99%

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Verleye

Wijtvliet

Abrams

et al. 2022

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background In the general population, the seroconversion rate after primary vaccination with two doses of an anti-SARS-CoV-2 mRNA vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here, we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients. Methods A systematic literature research was performed in Pubmed, Web of Science, and the Cochrane library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated. Results Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 (44.3%; 95% confidence interval (CI): [34.1%-54.7%]) as compared to such patients vaccinated with two doses of mRNA-1273 (58.4%; 95% CI: [47.2%-69.2%]). The relative seroconversion rate amounted 0.795 (95% CI: [0.732–0.864]). Conclusions This systematic review and meta-analysis indicates that, in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared to BNT162b2.

show abstract

“…Once again, it has been shown that earlier SARS-CoV-2 infection (additional natural immunization) has a positive effect on humoral response after vaccination [ 9 , 28 , 29 , 30 ]. The antibody titer after the third dose in PI-D patients was three times higher than that of IN-D subjects.…”

Section: Discussionmentioning

confidence: 99%

Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose

et al. 2022

Self Cite

View full text Add to dashboard Cite

The aim of this study was to analyze the waning of anti-spike (S) antibodies after mRNA vaccination against COVID-19 in maintenance dialysis patients, and to assess the safety and effectiveness of the complementary third dose. This was a prospective, longitudinal study in which we analyzed the kinetics of antibodies up to six months after a two-dose vaccination (first protocol) in infection-naïve dialysis patients (IN-Ds), previously infected dialysis patients (PI-Ds) and subjects without chronic kidney disease (the controls), as well as their humoral response to the third dose of the same mRNA vaccine (second protocol). The respective reduction in antibody titer after 3 and 6 months by 82.9% and 93.03% in IN-Ds (n = 109), 73.4% and 93.36% in PI-Ds (n = 32) and 75.5% and 88.8% in the controls (n = 20) was demonstrated. Consequently, a protective antibody titer above 141 BAU/mL was found in only 47.7% and 23.8% of IN-Ds after 3 and 6 months, respectively. After the third vaccine dose, a significant increase in antibody titer was observed in all groups, with increases by a factor of ×51.6 in IN-Ds, ×30.1 in the controls and ×8.4 in PI-Ds. The median antibody titer after the third dose differed significantly between groups, and was the highest in PI-Ds: PI-Ds, 9090 (3300–15,000) BAU/mL; the controls, 6945 (2130–11,800); IN-Ds, 3715 (1470–7325) (p < 0.001). In conclusion, we observed similar degrees of antibody waning in all patients. After 3 months, over half of the infection-naïve dialysis patients had a very low antibody titer, and almost twenty percent of them had no antibodies at all. The humoral response to the third dose was very good, raising their titer of antibodies to a higher level than those in the general population who have received the primary two-dose scheme. The results support the administration of a complementary third dose of the mRNA vaccine for dialysis patients as soon as possible.

show abstract

Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2. The COViNEPH Project

Cited by 8 publications

References 6 publications

Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients

Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose

Contact Info

Product

Resources

About